Coronary Disease - Other

JANS Article

Cardiac Shockwave Therapy in Addition to CABG Improves Myocardial Function in Ischemic Heart Failure: The CAST-HF Trial

June 27, 2024 | Mateo Marin-Cuartas

This study evaluated the outcomes after the use of cardiac shockwave therapy (SWT) combined with coronary artery bypass surgery (CABG) in patients with reduced left ventricular ejection fraction (LVEF) due to ischemic cardiomyopathy. Patients with...

JANS Article

A Promising Heart Drug Fails, Challenging a Long-Held Theory of Disease

September 10, 2026 | Vincent SierGold Contributor

Novo Nordisk reported that the ZEUS study, which involved more than 6,300 patients with heart disease or advanced kidney disease, failed to show a benefit for ziltivekimab vs placebo. Ziltivekimab...

JANS Article

Cardiac Shockwave Therapy in Addition to CABG Improves Myocardial Function in Ischemic Heart Failure: The CAST-HF Trial

June 27, 2024 | Mateo Marin-Cuartas

This study evaluated the outcomes after the use of cardiac shockwave therapy (SWT) combined with coronary artery bypass surgery (CABG) in patients with reduced left ventricular ejection fraction (LVEF) due...

JANS Article

Anomalous Aortic Origin of a Coronary Artery

June 20, 2024 | Jo Chikwe

The prevalence of anomalous aortic origin of a coronary artery is 0.4 percent to 0.8 percent. The decision to operate and choice of procedure can be challenging. This invited expert...

JANS Article

Mechanical Circulatory Support in Cardiogenic Shock — Persistence and Progress

May 18, 2024 | Aristotle ProtopapasGold Commentor

This article presents a succinct but comprehensive expert viewpoint on support in cardiogenic shock using the manuscript of the DanGer trial on promising results of Impella in a highly selected...

JANS Article

Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease

December 10, 2020 | Aristotle ProtopapasGold Commentor

An ad hoc interim analysis pursuant to previous publications raising concerns on Paclitaxel DCS in chronic critical and not-critical lower limb ischaemia. The short manuscript requires careful reading to form...

JANS Article

Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-Analysis

October 26, 2020 | Aristotle ProtopapasGold Commentor

Within the limitations of a meta-analysis, a useful work advancing that PCI may have a hitherto masked or hidden mortality

...
JANS Article

Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization

October 12, 2020 | Aristotle ProtopapasGold Commentor

An analysis, from the cardiology viewpoint, of the MI nomenclature issues around the external validity of the EXCEL trial that undermined the EACTS support of the relevant 2018 guidelines

...
JANS Article

Place and Causes of Acute Cardiovascular Mortality During the COVID-19 Pandemic

October 4, 2020 | Aristotle ProtopapasGold Commentor

The authors are concerned about the ‘deaths at home’ having the greatest contribution to the excess of acute cardiovascular deaths in that period of the recent epidemic, AND LOCKDOWN in...

JANS Article

Early Rhythm-Control Therapy in Patients With Atrial Fibrillation

October 1, 2020 | Aristotle ProtopapasGold Commentor

Death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome was reduced (P=0.005) by early pharmacogical or inteventional ablation for fast response-atrial fibrillation in...

JANS Article

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis

September 15, 2020 | Aristotle ProtopapasGold Commentor

An open-access large metanalysis on the utility and risks of antiplatelets after PCI. Of note, mortality was not a primary endpoint. The message is that long dual antiplatelet use is...

JANS Article

Initial Invasive or Conservative Strategy for Stable Coronary Disease

April 3, 2020 | Wei-Guo Ma

In the ISCHEMIA Trial, 5179 patients with moderate or severe myocardial ischemia were randomized equally into two groups based on initial management strategy: initial invasive strategy (angiography and revascularization when...

JANS Article

Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease – VOYAGER PAD

April 1, 2020 | Aristotle ProtopapasGold Commentor

Short but promising follow-up: the intervention appears again to trade off short-term peripheral vascular complications for hitherto semi-qualified MAJOR bleed in patients undergoing revascularization for peripheral vascular disease, for an...

LOAD MORE
ADVERTISE ON CTSNET